| Description | SRT 1720 is a selective activator of SIRT1 (EC1.5: 0.16 μM) and shows less potent activities on SIRT2 (EC1.5: 37 μM) and SIRT3 (EC1.5: 300 μM). |
| Target activity | SIRT1:0.16 μM (EC1.5), SIRT2:37 μM (EC1.5) |
| molecular weight | 542.48 |
| Molecular formula | C25H25Cl2N7OS |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 1mg/ml, Sonication is recommended. H2O: 25 mg/mL (46.08 mM), Sonication is recommended. |
| References | 1. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6 2. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61 3. Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice.,J Clin Invest. 2012 Jun 1;122(6):2032-45. 4. Gao D, et al. Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016 Nov;68(5):1191-1199. |
SRT 1720 dihydrochloride[925434-55-5(free base)]
CAS No.:
SRT 1720 is a selective activator of SIRT1 (EC1.5: 0.16 μM) and shows less potent activities on SIRT2 (EC1.5: 37 μM) a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.